Introduction
Immunoglobulin A (IgA) nephropathy is the most common form of glomerulonephritis in the world ( 1) . Initially, the prog-nosis of IgA nephropathy was presumed to be benign; however, it is now recognized that > 50% of patients develop insidious chronic renal failure (2) (3) (4) (5) (6) . The decline in renal function occurs slowly, steadily, and for the most part, silently, as does glomerulosclerosis. Such progressive deterioration of renal function and structure is not limited to IgA nephropathy but, rather, is common to many forms of chronic glomerular disease, and several key pathophysiologic mechanisms have been implicated in the progression (7) .
Pharmacologic blockade of angiotensin I converting enzyme (ACE)1 has been shown to significantly attenuate this progressive process in several experimental models (8, 9) , suggesting the potential pathogenic role of the renin-angiotensin system. Most recently, a multicenter study conducted on patients with diabetic nephropathy in the United States (10) has confirmed the notion suggested earlier by several investigators (11) (12) (13) that ACE inhibitor ameliorates the progressive decline of renal function in diabetic patients. Although results are variable (14, 15) , some studies (16, 17) also indicate that ACE inhibitor reduces proteinuria and attenuates progressive decline in renal function in IgA nephropathy as well. Of note, the important pathophysiologic role of the renin-angiotensin system has also been implicated in progressive disorders of the heart, notably cardiac hypertrophy and ischemic heart disease. While multiple studies have suggested an existence of correlation between genetic background in the renin-angiotensin system with evidence of heart disease (18) (19) (20) (21) (22) (23) (24) (25) (26) , one conducted in Germany by Schunkert et al. is of particular interest (26) . They studied the human ACE gene, which consists of 26 exons and spans 21 kb on chromosome 17 (27) . A deletion polymorphism of a 287-bp fragment of intron 16 of the ACE gene was detected. This polymorphism was found to be associated with the frequency of left ventricular hypertrophy (26) . While this deletion polymorphism is associated with elevated serum and cellular ACE levels (28, 29) , its association with blood pressure levels or ischemic heart disease varies between populations of different genetic and environmental backgrounds (21, (30) (31) (32) (33) (34) . Of interest, the study of Schunkert et al. (26) demonstrated that the association between the deletion polymorphism and left ventricular hypertrophy is significantly stronger when analysis is limited to normotensive individuals, suggesting that the polymorphism may influence local pathogenic events which involve renin-angiotensin. In this study, we have examined the possible role of the ACE deletion polymorphism on another target of renin-angiotensin-the kidney-and its association with the progressive loss of renal function in IgA nephropathy. Since Table I . Means of age and sex distributions were not distinguishable between controls and patient groups. In group 1, the mean period of observation after the onset of initial symptoms (13.7±0.8 yr) was similar to that in group 2 (12.0±1.3 yr). The mean values of urinary protein excretion rate in group 2 were not significantly different from those in group 1. The systolic blood pressure of the patients in group 2 was higher, on average, than that in group 1 (P < 0.05). The mean value of Cc, at the time of renal biopsy in group 2 patients was lower than that of group 1 (P < 0.05). 46 healthy subjects without history of proteinuria (22 and 24 of whom were female and male, respectively, ranging in age from 19 to 57 yr) were analyzed as controls. Plasma and urine creatinine concentrations were determined by an automated method, using Jaffe reaction. Urine protein concentration was measured by the Lowry method.
Extraction and amplification of genomic DNA. Genomic DNA was purified from peripheral blood with a blood DNA kit (QIAGEN Inc., Chatsworth, CA). Briefly, 10 ml of whole blood cells was lysed in 30 ml of distilled water and 10 ml of GI buffer containing an isotonic buffer designed to stabilize nuclei. Nuclei were collected by centrifugation and lysed in G2 buffer containing proteinase K. After digestion with proteinase K at 56°C overnight, the solution was passed over a resin column, which was then washed with 1 M NaCl. Genomic DNA was then desalted, and precipitated with isopropanol followed by washing in 70% ethanol. Genomic DNA was then suspended in 10 mN TrisHCl, 1 mM EDTA, pH. 8.0, and concentrations were measured by absorbance at 260 nm.
To determine the ACE genotype of the patients, a genomic DNA fragment on intron 16 of the ACE gene was amplified by PCR according to Rigat's method (35) . PCR amplification products were obtained using 50-,ql reactions (1 .tg genomic DNA, 500 pmol primers, 0.5 mM each deoxy-ATP, GTP, CTP, TTP, 3 mM MgCl2, 1 U Taq DNA polymerase [Takara, Ootsu, Shiga, Japan], 50 mM KCl, 0.001% gelatin, and 10 mM Tris-HCl, pH 8.3) with 10 min of denaturation at 94°C, followed by 30 cycles of 1 min at 940C, 1 min at 580C (annealing), and 2 min at 72°C (extension) in a thermal cycler (PC-700; ASTEC, Fukuoka, Japan). Reaction was terminated at 720C for 2 min. The forward and reverse primers used were 5'-CTGGAGACCACTCCCATCCTTTCT and 5 '-GATGTGGCCATCACATTCGTCAGAT, respectively. The am-plified ACE gene fragments were separated by agarose gel electrophoresis. Fragments without insertion (D allele) and with insertion (I allele) of -190 and -490 bp, respectively, were detected on a 1% agarose gel containing ethidium bromide.
Recently, a study (36) reported that PCR amplification using a primer pair that recognizes insertion-specific sequence identifies 4-5% of ID genotypes that have been misclassified as DD when only a flanking primer pair was used. To increase the specificity of DD genotyping, therefore, we used a primer pair that recognized the insertion-specific sequence based on a published DNA sequence. Thus, PCR amplifications were performed with an insertion-specific primer pair (5'TGG-GACCACAGCGCC CGCCACTAC 3' and 5 'TCGCCAGCCCTC-CCATGCCC-ATAA 3'), with 25-al reactions (0.5 Iug genomic DNA, 500 pmol of primers, 0.5 mM each deoxy-ATP, GTP, CTP, TTP, 1 Statistical analysis was performed for urine protein excretion by using one-way ANOVA. The data for urine protein excretion were analyzed using the repeated-measures ANOVA to evaluate the statistical significance of the influence of the ACE gene polymorphism on the antiproteinuric effect of ACE inhibitor administration. To evaluate the statistical significance for the difference in the antiproteinuric effect of ACE inhibitor administration between DD versus ID and II, or ID versus II genotype, the one factor ANOVA was used. The data for Ccr were analyzed using the repeated-measures ANOVA to evaluate the statistical significance of the influence of the ACE gene polymorphism on the renoprotective effect of ACE inhibitor administration. P < 0.05 was regarded as being statistically significant.
Results
The frequency of DD genotypes. In the control group, the frequencies of the D and I alleles were 33 and 67%, and the frequencies of the DD, ID, and II genotypes observed were 7, 52, and 41%, respectively. These data are similar to the published data for the Japanese general population (36) (37) (38) . In IgA patients with stable renal function (group 1), the frequencies of the DD, ID, and II genotypes were 16.0, 36.0, and 48.0%, respectively ( Fig. 1 A) , with gene frequencies of D and I allele of 34 and 65%. The expected values which are predicted by the assumption of Hardy-Weinberg equilibrium in control group (DD:ID:II = 11:44:45%, X2 = 1.88, NS) and in group 1 (DD:ID:II = 12:44:44%, x2 = 1.91, NS) were shown to be similar to those observed in these patients. In patients with declining function (group 2), however, the frequencies of genotype (DD:ID:II = 43:29:29%) were significantly different from those seen in the control group (X2 = 14.35, P < 0.001).
The difference in distribution pattern between group 1 and 2, however, did not reach statistical significance for this whole patient population comparison (Fig. 1 A) was significantly different (X2 = 6.96, P < 0.05) (Fig. 1 B) .
Of the above 45 (Fig. 1 C) .
To estimate the relative risk for the progressive loss of renal function that the DD genotype carries, the ratio of the DD genotype versus the pooled frequency of the ID and II genotypes in group 2 was compared with that in group 1 (Fig. 2) Fig. 3 . These three groups were indistinguishable for age, sex, baseline blood pressure, urinary protein excretion rate, serum creatinine levels, and Cc, (Table II) In this study, it was found that a deletion polymorphism in the ACE gene has a significant association with the incidence of progressive deterioration of renal function in IgA nephropathy. The patients with progressive decline in renal function were also characterized by a higher incidence of hypertension and an initially mildly reduced renal function, a finding consistent with the prevailing notion that these two clinical and laboratory findings are risk factors predicting the progression to renal failure in this disease (39) (40) (41) (42) . Our data suggest the possibility that these and other initial clinical and laboratory signs are also associated with the presence of the ACE gene deletion polymorphism. For example, the frequency of the DD genotype was higher in patients with declining renal function (43%) than in those with stable renal function ( 16%). Also, it was of higher frequency in the IgA nephropathy patient population as a whole (30%) than in the Japanese general population, which is estimated to be -10% (39) . These associations suggest that the presence of the DD genotype may shift IgA nephropathy from mild to severe, and nephropathy from subclinical to overt. Thus, the presence or absence of the DD ACE genotype may modify the severity and/or course of subclinical IgA nephropathy that 17 7
Odds ratios were unadjusted for age and sex. CI, confidence interval. * P < 0.05, ' P < 0.01, P < 0.005.
has been detected in screening of one million school children in Japan (43 In the present study, detailed analysis of our IgA nephropathy patients further revealed that, in a subpopulation of patients with normal renal function and in another subpopulation of those without hypertension at the time of biopsy, a significant association also exists between the presence of polymorphism and progressive loss of renal function. These results are analogous to those occurring in cardiomyopathy as previously discussed (18, 19, 26) . Indeed, the odds ratio to develop left ventricular hypertrophy was found by Schunkert et al. (26) to be substantially higher among normotensive than hypertensive individuals. From the study of cardiomegaly, one may infer that the deleterious effects of the ACE D polymorphism may be mediated through pathogenic effects at the local tissue level rather than systemic hypertension. However, without extensive blood pressure monitoring data, the possibility remains that a subtle ACE gene-dependent abnormality in blood pressure may mediate the progression of IgA nephropathy.
Inspection of data from individual patients with progressive IgA nephropathy suggests that other factors contribute to the progression of the disease. For example, the clinical course of these patients was not uniform, i.e., some patients required chronic dialysis within 5-10 yr after onset, and the renal function of others slowly progressed to renal failure over a period of 20 yr after onset of the first symptoms. Variable histologic findings were also observed in the patients with progressive IgA nephropathy (42, 45, 46 In many chronic renal diseases, administration of an ACE inhibitor leads to a significant attenuation of proteinuria (16, 49, 50) . Interestingly, it has been recently reported (51) that, in patients with insulin-dependent diabetes with normal renal function, the absence of the D polymorphism decreases the probability of development of microalbuminuria or proteinuria, but a strong correlation was not demonstrated in another study (52) . Thus, in both IgA nephropathy and diabetic nephropathy, the presence of proteinuria may act as a risk factor for chronic renal failure, conceivably because proteinuria and progression share the same genetic risk factor, namely, the D polymorphism of the ACE gene. However, it is speculative since it has not been established in diabetes that the D polymorphism is associated with progression to renal failure, nor that, in IgA nephropathy, proteinuria per se predicts the course of the disease. Furthermore, all of our patients were on a variety of medications which might themselves modify the levels of urinary protein and hypertension.
Because ACE inhibitors, which dampen the increased ACE activity, are readily available, the genetic predisposition of some IgA patients can, at least theoretically, be overcome therapeutically. In this regard, in IgA nephropathy, administration of an ACE inhibitor has been demonstrated to reduce urinary protein excretion and to attenuate the progression of glomerular injury to a variable degree ( 17 ) . The apparent variability in the effectiveness of ACE inhibition on proteinuria and progressive decline in renal function in IgA nephropathy may be attributed to the strong dependency of the efficacy of ACE inhibition on the genetic background of patients. In our study, proteinuria was indeed significantly decreased after ACE inhibition in patients with the DD genotype while it was without statistically significant effect in patients with II and ID genotypes. In addition, CCr was not significantly altered after ACE inhibition in patients regardless of the ACE genotype, due presumably in part to the short observation period.
In summary, we observed a significant association between the D polymorphism of the ACE gene and the progressive loss of renal function in patients with IgA nephropathy. Moreover, presence of this polymorphism was associated with increased efficacy of ACE inhibition on proteinuria. Further studies are warranted to verify these findings and to clarify if, in IgA nephropathy patients with the D polymorphism, their predisposition to renal failure can be significantly modified or altered by ACE inhibition or another pharmacologic intervention.
